|
Session 101
Poster Abstracts
Mechanisms of Drug Resistance: Entry Inhibitors
Monday, 1:30 - 3:30 pm
Poster Hall |
| 595 |
Both HIV-1 gp120 and gp41 Envelope Glycoproteins Contribute to Natural Variability in Enfuvirtide Susceptibility
Signe Fransen*, J Whitcomb, T Wrin, J Toma, C Petropoulos, and W Huang
Monogram Biosci, South San Francisco, CA, US |
| 596 |
Characterization of Gp41 Evolution in a Large Cohort of HIV-1-infected Patients Receiving Long-term T-20 Treatment as a Single Active Drug
Stefano Aquaro*1, V Svicher1, R D'Arrigo2, U Visco-Comandini2, A Antinori2, M Santoro1, G Di Perri3, S Lo Caputo4, P Narciso2, and C F Perno2
1Univ of Tor Vergata, Rome, Italy; 2Natl Inst of Infectious Diseases, L Spallanzani, Rome, Italy; 3Univ of Turin, Italy; and 4Hospital SM Annunziata, Florence, Italy |
| 597 |
Continued GP41 Evolution after Interruption of Enfuvirtide: Evidence for Ongoing Immunologic Pressure in Advanced HIV Disease
Christina Kitchen*1, M Suchard1, J Lu2, R Hoh3, D Kuritzkes2, and S Deeks3
1David Geffen Sch of Med, Univ of California, Los Angeles Med Ctr, US; 2Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, US; and 3Univ of California, San Francisco, US |
| 598 |
Resistance to the CCR5 Antagonist Maraviroc Is Characterised by Dose-Response Curves that Display a Reduction in Maximal Inhibition
M Mosley1, C Smith-Burchnell1, J Mori1, M Lewis1, M Stockdale1, W Huang2, J Whitcomb2, C Petropoulos2, M Perros1, and Mike Westby*1
1Pfizer Global R&D, Sandwich, UK and 2Monogram Biosci, South San Francisco, CA, US |
| 599 |
Evolution and Recombination of Genes Encoding Drug Resistance and Co-receptor Usage during ART
C Kitchen1, B Shi2, B Weiser2, S Philpott2, M Suchard1, K Anastos3, W Meyer Iii4, S Back3, M Parker2, and Harold Burger*2
1David Geffen Sch of Med, Univ of California, Los Angeles Med Ctr, US; 2Wadsworth Ctr, New York State Dept of Hlth, Albany, US; 3Albert Einstein Coll of Med, Bronx, NY, US; and 4Quest Diagnostics, Inc, Baltimore, MD, US |
|
